OOIR: Observatory of International Research

Papers

(The H4-Index of Osteoporosis International is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Comment on “Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer”: Waxing-Waning Serum Calcium following Denosumab use in a patient with Polyostotic Paget’s Disease of Bone	460
A promising strategy for the diagnosis, treatment, and prevention of osteoporosis (EMS strategy)	157
Dual-energy x-ray absorptiometry scanner mismatch in follow-up bone mineral density testing	149
Authors’ reply to 2nd comment on: effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aero	123
Return on investment of fracture liaison services: a systematic review and analysis	94
One versus 2 years of alendronate following denosumab: the CARD extension	80
Follicle-stimulating hormone is associated with low bone mass in postmenopausal women	74
Correction to: Author response to the comments on our article Relatively low and moderate pre-fracture serum 25-hydroxyvitamin D levels associated with the highest survival in elderly hip fracture pat	73
RETRACTED ARTICLE: Evaluation of bone mineral density (BMD) and trabecular bone score (TBS) in pheochromocytoma and paraganglioma; a multi-centric case–control study from India	71
Authors’ reply to comment on: Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aerobic	67
The clinical trial landscape of anti-RANKL agents for osteoporosis: current status and future directions	66
The association between blood cadmium levels and bone mineral density in U.S. adolescents aged 12–19 years	60
The incidence of subsequent contralateral hip fracture and factors associated with increased risk: the IMPACT Contralateral Fracture Study	59
Scaffolds: a biomaterial engineering in targeted drug delivery for osteoporosis	58
Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk	54
Changes in spinal sagittal balance after a new osteoporotic vertebral compression fracture	51
The effects of β-carotene on osteoporosis: a systematic review and meta-analysis of observational studies	49
Association between SGLT2 inhibitor use and the risk of vertebral augmentation after initial osteoporotic vertebral fracture in patients with type 2 diabetes	46
Postmenopausal osteoporosis and the global burden of fractures: a gynecologist’s perspective	46
Bone mineral density assessment using radiofrequency echographic multispectrometry (REMS) in patients before and after total hip replacement	44
Trajectories of oral bisphosphonate use after hip fractures: a population-based cohort study	44
The link between osteoporosis and cardiovascular diseases: a review of shared mechanisms, risk factors, and therapeutic approaches	43
Post-fracture care and predictors of anti-osteoporotic treatment in Switzerland: a nationwide health claims analysis	42
Impact of the guidance on fracture Liaison Services and the introduction of a new fee for secondary fracture prevention in Japan: Implementation of secondary fracture prevention during hospitalization	42
Epidemiology of pelvic and acetabular fractures in the USA from 2007 to 2014	39

Successful treatment using asfotase alfa for delayed healing of a metatarsal stress fracture in an adolescent girl with hypophosphatasia	38
Atypical femoral fracture after denosumab for the treatment of osteoporosis in bisphosphonate naïve patients: two further cases	36
Association between dental diseases and oral hygiene care and the risk of vertebral fracture: a nationwide cohort study	34
Patients not taking a previously prescribed bone active medication now prescribed medication through Ontario FLS	33
Artificial intelligence insights into osteoporosis: comment	32
International consensus on the non-pharmacological and non-surgical management of osteoporotic vertebral fractures	32
Author response to: Comment from Dongdong Cao, et al. on: Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nati	32
Evaluating the impact of COVID-19 on DXA waiting lists and osteoporosis prescription trends in England 2019–2023	32
Latent metabolic bone disease, skeletal dysplasia and other conditions related to low bone formation among 38 patients with subtrochanteric femoral fractures: a retrospective observational study	32